- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04949399
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence
The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence.
Study doctors will randomize participants into 1 of the 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 400 participants will be enrolled in the study in the United States and Canada.
Participants will receive either intramuscular injections of onabotulinumtoxinA (BOTOX) or placebo.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at the study site.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E1
- Humphrey Cosmetic Dermatology /ID# 229522
-
-
Ontario
-
Burlington, Ontario, Canada, L7N 3N2
- Dermetics Cosmetic Dermatology /ID# 229482
-
Cobourg, Ontario, Canada, K9A 0Z4
- Dr Melinda Gooderham Medicine Profession /ID# 229456
-
Richmond Hill, Ontario, Canada, L4B 1A5
- The Center For Dermatology /ID# 229481
-
-
-
-
Arizona
-
Glendale, Arizona, United States, 85308
- Advanced Research Associates - Glendale /ID# 229256
-
Scottsdale, Arizona, United States, 85255-4134
- Clear Dermatology & Aesthetics Center /ID# 229252
-
-
California
-
Encino, California, United States, 91436-2124
- Clinical Testing of Beverly Hills /ID# 229946
-
Los Angeles, California, United States, 90045
- Dermatology Research Associates /ID# 229949
-
Newport Beach, California, United States, 92663
- Steve Yoelin MD Medical Associate Inc /ID# 229420
-
San Diego, California, United States, 92121-2119
- Cosmetic Laser Dermatology /ID# 229245
-
Santa Monica, California, United States, 90404-2208
- Ava T. Shamban MD - Santa Monica. /ID# 229421
-
Solana Beach, California, United States, 92075-2228
- Art of Skin MD /ID# 229255
-
-
Connecticut
-
Westport, Connecticut, United States, 06880
- DMR Research PLLC /ID# 229938
-
-
Florida
-
Bradenton, Florida, United States, 34209-5642
- Susan H. Weinkle MD /ID# 229419
-
West Palm Beach, Florida, United States, 33401-2712
- Research Institute of the Southeast, LLC /ID# 229234
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260-2386
- Laser and Skin Surgery Center of Indiana /ID# 229515
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Coleman Center For Cosmetic Dermatologic Surgery /ID# 229414
-
New Orleans, Louisiana, United States, 70115
- Delricht Research /ID# 229248
-
-
Maryland
-
Baltimore, Maryland, United States, 21208-6391
- Aesthetic Center at Woodholme /ID# 229836
-
Hunt Valley, Maryland, United States, 21030-3216
- Maryland Dermatology Laser, Skin, & Vein Institute /ID# 229260
-
-
New Jersey
-
Montclair, New Jersey, United States, 07042
- Image Dermatology, P.C. /ID# 229244
-
-
New York
-
New York, New York, United States, 10016-4974
- Laser & Skin Surgery Center of New York /ID# 229423
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27517-9901
- Aesthetic Solutions /ID# 229241
-
Wilmington, North Carolina, United States, 28403
- Wilmington Dermatology Center /ID# 229246
-
-
Ohio
-
Dublin, Ohio, United States, 43016
- Aventiv Research Dublin /ID# 229254
-
-
Pennsylvania
-
Newtown Square, Pennsylvania, United States, 19073-2228
- KGL Skin Study Center, LLC /ID# 229253
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203-1513
- Nashville Center for Laser and Facial Surgery /ID# 229237
-
-
Texas
-
Dallas, Texas, United States, 75231
- Dallas Plastic Surgery Institute /ID# 229258
-
-
Virginia
-
Arlington, Virginia, United States, 22209
- SkinDC /ID# 229251
-
-
Washington
-
Spokane, Washington, United States, 99202
- Premier Clinical Research /ID# 229261
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study specific procedures
Are willing and able to comply with procedures required in the protocol
Adult male or female, at least 18 years old at the time of signing the informed consent
Good health as determined by medical history, physical examination, vital signs, and investigator's judgment
Exclusion Criteria:
Any medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)
Anticipated need for surgery or overnight hospitalization during the study
Females who are pregnant or breastfeeding and are considering becoming pregnant or donating eggs during the study
Known immunization or hypersensitivity to any botulinum toxin serotype
History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months
Lower facial and neck hair, scarring (e.g., acne), or other abnormal variations that may interfere with photography (such that photograph is not acceptable)
Tattoos, jewelry, or clothing that cannot be removed, and that obscure the target area of interest
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BOTOX
BOTOX will be injected into the platysma muscle on Day 1
|
Injection
Other Names:
|
Placebo Comparator: Placebo
Placebo will be injected into the platysma muscle on Day 1
|
Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events
Time Frame: Day -14 to Day 120
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment.
The investigator assesses the relationship of each event to the use of the study.
A serious adverse event (SAE) is an event that results in death, is life threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event, that based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.
Treatment-emergent adverse events/ treatment emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of the study drug.
|
Day -14 to Day 120
|
Composite Achievement of Grade 1 or 2 (Minimal or Mild) and at Least a 2-Grade Improvement from Baseline Based on Both Investigator's Assessment using C-APPS and Participant's Self-Assessment using P-APPS
Time Frame: Day 1 to Day 14
|
The Clinician Allergan Platysma Prominence Scale (C-APPS) evaluates platysma prominence and is a static measurement encompassing visual examination of the platysma muscle ranging from 1 - Minimal to 5- Extreme. The Participant Allergan Platysma Prominence Scale (P-APPS) evaluates platysma prominence and is a single-item measure that is accompanied by a 5-grade photonumeric scale ranging from 1 - Minimal to 5 - Extreme. |
Day 1 to Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants with Responses of "Satisfied" or "Very Satisfied" on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction (Follow-up) Item 5 (effect of treatment)
Time Frame: Day 14
|
The ANLFQ is a 11-item measure that assesses how satisfied the participants are with the treatment they received for the appearance of their neck and lower face.
|
Day 14
|
Percentage of Participants with Responses of 'Not at all bothered' or 'A little bothered' on the Bother Assessment Scale - Platysma Prominence (BAS-PP) Scale Item 2 (Jawline)
Time Frame: Day 14
|
The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).
|
Day 14
|
Percentage of Participants with Responses of 'Not at all Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 1 (Vertical Neck Bands)
Time Frame: Day 14
|
The BAS-PP Scale is a 2-item measure that asks participants to rate how bothered they are by the appearance of their vertical neck bands (Item 1) and jawline (Item 2) where items are rated from 1 (Not at all bothered) to 5 (Extremely bothered).
|
Day 14
|
Change from baseline on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Impacts summary score
Time Frame: Day 1 to Day 14
|
The Appearance of Neck and Lower Face Questionnaire: Impacts is a 7-item measure that assesses the psychosocial impact of the appearance of the neck and lower face.
|
Day 1 to Day 14
|
Percentage of Participants who Achieved Grade 1 or 2 (Minimal or Mild) According to Participant's Assessment using P-APPS
Time Frame: Day 1 to Day 120
|
The P-APPS evaluates platysma prominence and is a single-item measure that is accompanied by a 5-grade photonumeric scale ranging from 1 - Minimal to 5 - Extreme.
|
Day 1 to Day 120
|
Percentage of Participants who Achieved at Least 1-Grade Improvement from Baseline Based on Investigator's Assessment Using C-APPS
Time Frame: Day 1 to Day 120
|
The C-APPS evaluates platysma prominence and is a static measurement encompassing visual examination of the platysma muscle ranging from 1 - Minimal to 5- Extreme.
|
Day 1 to Day 120
|
Percentage of Participants who Achieved at Least 1-Grade Improvement from Baseline Based on Participant's Assessment using P-APPS
Time Frame: Day 1 to Day 120
|
The P-APPS evaluates platysma prominence and is a single-item measure that is accompanied by a 5-grade photonumeric scale ranging from 1 - Minimal to 5 - Extreme.
|
Day 1 to Day 120
|
Percentage of Participants who Achieved Grade 1 or 2 (Minimal or Mild) according to Investigator's Assessment using C-APPS
Time Frame: Day 1 to Day 120
|
The C-APPS evaluates platysma prominence and is a static measurement encompassing visual examination of the platysma muscle ranging from 1- Minimal to 5- Extreme.
|
Day 1 to Day 120
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: ALLERGAN INC., Allergan
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M21-309
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Platysma Prominence
-
AllerganCompletedPlatysma ProminenceUnited States, Belgium, Canada, Germany, United Kingdom
-
Merz Aesthetics GmbHCompletedPlatysma ProminenceUnited States
-
AllerganCompleted
-
AllerganCompletedPlatysma ProminenceUnited States, Canada
-
Clinical Testing of Beverly HillsGalderma R&DActive, not recruiting
-
AbbVieRecruitingMasseter Muscle ProminenceJapan
-
AbbVieRecruitingMasseter Muscle ProminenceBulgaria, Germany, Spain, Italy, United Kingdom, Belgium, France
-
AllerganCompletedMasseter Muscle ProminenceUnited States
-
AllerganCompletedMasseter Muscle ProminenceCanada, China, Taiwan
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States